VIDEO: Molecular tests may provide valuable prognostic information for thyroid cancer
Click Here to Manage Email Alerts
In this video, John M. Skaugen, MD, an assistant professor of pathology at University of Pittsburgh discusses his study presented at the American Thyroid Association 2022 annual meeting.
The retrospective study, a highlighted poster, looked to establish molecular characteristics of the ThyroSeq v3 (TSv3) Cancer Risk Classifier (CRC), which was evaluated as a tool to predict thyroid cancer recurrence preoperatively in subjects with suspicion for malignancy cytology nodules.
"In our group of about 100 patients we found no recurrences for our lowest risk group, which was about 20 patients; intermediate risk group was about 10% risk of recurrence and that was in 66 patients; and then the high-risk group — not huge — but about 14 patients and 55% risk of recurrence. So we found a nice correlation," Skaugen said.
"It's exciting that we're starting to see more and more that these molecular tests can give some prognostic information, especially preoperatively," he said.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts